Company profile: Allay Therapeutics
1.1 - Company Overview
Company description
- Provider of analgesic products for post-surgical pain management and recuperation, including ATX-101, which delivers controlled-release bupivacaine at the surgical site to provide weeks of pain relief after total knee replacement. Offers a proprietary technology platform combining non-opioid analgesics and biopolymers to create dissolvable candidates for localized, extended pain relief.
Products and services
- Proprietary Technology Platform: Architects biopolymer-integrated assemblies combining non-opioid analgesics and biopolymers, forming dissolvable constructs for localized pain relief sustained over extended periods (biopolymer-integrated)
- ATX-101: Engineers a bupivacaine-based product delivering controlled release directly at the surgical site, yielding weeks of pain relief after total knee replacement (bupivacaine-based)
- Dissolvable Analgesic Candidates: Produces non-opioid, biopolymer-based candidates intended for localized pain relief maintained over extended periods, generated through the company’s platform (non-opioid)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Allay Therapeutics
Remedy Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage small molecule drug therapies for acute central nervous system disorders, developing treatments that target NCCa-ATP channels in traumatic brain injury, stroke, and spinal cord injury, including RP-1127, an intravenous glyburide inhibitor acting through type-1 sulfonylurea antagonism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Remedy Pharmaceuticals company profile →
Newronika
HQ: Italy
Website
- Description: Provider of innovative brain neuromodulation technologies that translate deep biosignal decoding into clinical practice to improve treatments, health, and wellness. Products include AlphaDBS, a closed-loop implant that adapts stimulation based on real-time neuronal biosignal activity, and WebBioBank, a cloud database for collecting and analyzing biosignal data from the AlphaDBS implantable pulse generator.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Newronika company profile →
Acticor Biotech
HQ: France
Website
- Description: Provider of biopharmaceutical development of glenzocimab, a humanized monoclonal antibody fragment targeting platelet GPVI with antithrombotic properties without increasing bleeding risk, for the acute phase of ischemic stroke. Runs clinical trials: ACTISAVE, ACTIMIS, and GREEN in stroke, LIBERATE in myocardial infarction, and GARDEN in SARS-CoV-2-related ARDS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acticor Biotech company profile →
Akome Biotech
HQ: Canada
Website
- Description: Provider of psychedelic-based pharmaceuticals for rare diseases and mental disorders, targeting treatments for cluster headaches, Alzheimer’s disease, and depression, serving patients suffering from stroke and neurological illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akome Biotech company profile →
Enterin
HQ: United States
Website
- Description: Provider of biotechnology therapeutics developing oral and subcutaneous compounds: ENT-01 displaces alpha-synuclein aggregates from enteric nerve cells to improve gut-brain signaling, being developed for Parkinson’s Disease and its non-motor symptoms; ENT-03 reverses central insulin resistance to increase insulin sensitivity and normalize blood sugar, being developed for obesity, type 2 diabetes, and Alzheimer’s Disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enterin company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Allay Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Allay Therapeutics
2.2 - Growth funds investing in similar companies to Allay Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Allay Therapeutics
4.2 - Public trading comparable groups for Allay Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →